Brief: Oramed Reaches 25% Enrollment In Its Second Of Two Concurrent Phase 3 Oral Insulin Trials

Oramed Pharmaceuticals

24/08/2021 15:38

Aug 24 (Reuters) - Oramed Pharmaceuticals Inc  ORMP.O :
    * ORAMED REACHES 25% ENROLLMENT IN ITS SECOND OF TWO
CONCURRENT
PHASE 3 ORAL INSULIN TRIALS
    * ORAMED PHARMACEUTICALS INC - ORA-D-013-2 IS SECOND OF TWO
PHASE
3 TRIALS UNDER FDA PROTOCOL CURRENTLY UNDERWAY
    * ORAMED PHARMACEUTICALS INC - ORA-D-013-1, LARGER AND FIRST
OF
2-PART TRIAL TO COMMENCE, NEARS 65% ENROLLMENT

Source text for Eikon:  ID:nPnblMdYNa 
Further company coverage:  ORMP.O 

 (((Reuters.Briefs@thomsonreuters.com);))